CHADS₂ Score Calculator
Estimates annual stroke risk in patients with non-valvular atrial fibrillation. Used to guide decisions about anticoagulation therapy. The CHADS₂ score identifies patients who are likely to benefit from oral anticoagulation versus those at sufficiently low risk to consider aspirin or no therapy.
Calculate CHADS₂ Score
Select the risk factors present in your patient with non-valvular atrial fibrillation. Each criterion contributes 1 point except prior stroke/TIA, which contributes 2 points. The maximum score is 6. For a more refined risk assessment, consider the CHA₂DS₂-VASc score, which is now preferred by most current guidelines.
The CHADS₂ score applies to non-valvular atrial fibrillation only. Patients with moderate-to-severe mitral stenosis or mechanical heart valves are at high stroke risk regardless of CHADS₂ score and require anticoagulation (typically warfarin). Current guidelines from the ESC, AHA/ACC, and NICE now recommend the CHA₂DS₂-VASc score for more granular risk stratification, as it better identifies truly low-risk patients.
Understanding the CHADS₂ Score
Atrial fibrillation (AF) increases the risk of ischaemic stroke approximately five-fold. The mechanism is stasis of blood in a fibrillating left atrium — particularly in the left atrial appendage — leading to thrombus formation. These thrombi can embolise to the cerebral circulation, causing cardioembolic stroke, which tends to be larger and more disabling than strokes from other causes.
The CHADS₂ score was developed by Gage et al. in 2001 by combining elements from two earlier schemes (the AFI and SPAF risk stratification models). It was validated in a cohort of 1,733 Medicare beneficiaries aged 65–95 years with non-valvular AF who were not receiving anticoagulation at discharge. The score demonstrated a clear dose–response relationship between the number of risk factors and the annual stroke rate.
The CHADS₂ Acronym
Why the S Is Worth 2
A prior stroke or TIA is by far the strongest predictor of future stroke in AF patients. The annual recurrence rate of stroke in AF patients with a prior cerebrovascular event is approximately 10–12% without anticoagulation — roughly 2.5 times higher than the next strongest risk factor. This is why it carries a double weighting in the score.
Notably, the CHADS₂ score does not distinguish between ischaemic stroke, TIA, and systemic thromboembolism — all are counted equally as the “S₂” criterion, as they all indicate the patient has already formed and embolised a thrombus.
Key distinction — CHADS₂ vs. CHA₂DS₂-VASc: The CHADS₂ score classifies a substantial proportion of patients as “intermediate risk” (score 1), a category where the anticoagulation decision is unclear. The CHA₂DS₂-VASc score (Lip, 2010) added three additional risk factors — vascular disease, age 65–74, and female sex — to better stratify this intermediate group. Most current guidelines now use CHA₂DS₂-VASc as the primary risk assessment tool, reserving CHADS₂ for initial screening or settings where the simpler score is preferred.
Interpretation & Annual Stroke Rates
The table below shows the adjusted annual stroke rates from the original CHADS₂ validation study (Gage et al., 2001) in patients not receiving anticoagulation. These rates increase in a near-linear fashion with each additional point.
| CHADS₂ Score | Annual Stroke Rate | 95% CI | Risk Category | Suggested Therapy |
|---|---|---|---|---|
| 0 | 1.9% | 1.2–3.0% | Low | Aspirin or no therapy* |
| 1 | 2.8% | 2.0–3.8% | Low-Moderate | Aspirin or anticoagulation (individualise)* |
| 2 | 4.0% | 3.1–5.1% | Moderate | Oral anticoagulation recommended |
| 3 | 5.9% | 4.6–7.3% | High | Oral anticoagulation recommended |
| 4 | 8.5% | 6.3–11.1% | High | Oral anticoagulation recommended |
| 5 | 12.5% | 8.2–17.5% | Very High | Oral anticoagulation strongly recommended |
| 6 | 18.2% | 10.5–27.4% | Very High | Oral anticoagulation strongly recommended |
*Current guidelines (ESC 2020, AHA/ACC 2019) no longer recommend aspirin as an alternative to anticoagulation for stroke prevention in AF, as the bleeding risk of aspirin approaches that of anticoagulants without equivalent stroke reduction.
The traditional teaching that CHADS₂ = 0 is “low risk” may be misleading. A 1.9% annual stroke rate still means approximately 1 in 50 patients will have a stroke each year. When these patients are further evaluated with CHA₂DS₂-VASc, many will score ≥ 1 (e.g., age 65–74 or vascular disease) and may benefit from anticoagulation. This is the primary reason CHA₂DS₂-VASc has superseded CHADS₂ — it is better at identifying the truly low-risk patients (CHA₂DS₂-VASc = 0 in males or 1 in females) who can safely forgo anticoagulation.
Anticoagulation Options & Bleeding Risk
Once the CHADS₂ score identifies a patient who should receive anticoagulation, the next clinical decision is which agent to use and how to balance stroke prevention against bleeding risk.
Anticoagulation Agents
DOACs are now the preferred first-line anticoagulants for non-valvular AF in most guidelines (ESC, AHA/ACC, NICE). They offer comparable or superior stroke prevention to warfarin with lower rates of intracranial haemorrhage, predictable pharmacokinetics, no routine monitoring requirement, and fewer drug/food interactions.
- Dabigatran (Pradaxa): Direct thrombin inhibitor. 150 mg BID was superior to warfarin for stroke prevention; 110 mg BID was non-inferior with lower bleeding. Renally cleared — dose-reduce or avoid in severe CKD (eGFR < 30). Reversal agent: idarucizumab (Praxbind).
- Rivaroxaban (Xarelto): Factor Xa inhibitor. 20 mg daily with food. Non-inferior to warfarin. Hepatically and renally cleared. Dose-reduce to 15 mg daily if CrCl 15–50 mL/min.
- Apixaban (Eliquis): Factor Xa inhibitor. 5 mg BID. Superior to warfarin for stroke prevention with significantly less major bleeding and intracranial haemorrhage (ARISTOTLE trial). Dose-reduce to 2.5 mg BID if ≥ 2 of: age ≥ 80, weight ≤ 60 kg, creatinine ≥ 1.5 mg/dL. Often preferred in elderly and CKD patients.
- Edoxaban (Savaysa/Lixiana): Factor Xa inhibitor. 60 mg daily. Non-inferior to warfarin. Dose-reduce to 30 mg if CrCl 15–50 mL/min, weight ≤ 60 kg, or concomitant P-gp inhibitors. Not for CrCl > 95 mL/min (reduced efficacy).
Reversal for Xa inhibitors: andexanet alfa (Andexxa), or prothrombin complex concentrate (PCC) if unavailable.
Warfarin remains the standard anticoagulant for valvular AF (mechanical valves, moderate-to-severe mitral stenosis) and in situations where DOACs are contraindicated or unavailable. Target INR is 2.0–3.0 for stroke prevention in AF. Time in therapeutic range (TTR) should exceed 65–70% for optimal benefit; poor TTR is associated with both increased stroke and bleeding.
Key limitations include: narrow therapeutic window, frequent monitoring (INR checks), extensive drug and food interactions (vitamin K–rich foods, CYP2C9 substrates), slow onset and offset, and genetic variation in metabolism (CYP2C9, VKORC1 polymorphisms). Despite these, warfarin remains essential where DOACs are contraindicated (e.g., mechanical valves, severe CKD with eGFR < 15, antiphospholipid syndrome). Reversal: vitamin K (slow), PCC or FFP (rapid).
The anticoagulation decision requires balancing stroke risk (CHADS₂ / CHA₂DS₂-VASc) against bleeding risk. The HAS-BLED score is the most widely used bleeding risk tool: Hypertension (uncontrolled, SBP > 160), Abnormal renal/liver function, Stroke history, Bleeding history or predisposition, Labile INR (if on warfarin), Elderly (> 65), Drugs (antiplatelet agents, NSAIDs) or alcohol excess.
A HAS-BLED score ≥ 3 indicates increased bleeding risk, but this does not contraindicate anticoagulation — rather, it signals the need to address modifiable risk factors (control blood pressure, stop unnecessary NSAIDs/antiplatelets, manage alcohol, improve INR control or switch to a DOAC). In most cases, the net clinical benefit of anticoagulation still favours treatment, even in patients with elevated HAS-BLED scores, because the consequences of cardioembolic stroke (death, severe disability) generally outweigh the consequences of anticoagulant-related bleeding.
CHADS₂ vs. CHA₂DS₂-VASc
The CHA₂DS₂-VASc score (Lip et al., 2010) extends the CHADS₂ by adding three additional risk factors: vascular disease (prior MI, peripheral arterial disease, aortic plaque), age 65–74 (as a separate, lower-weighted criterion from age ≥ 75), and female sex (Sc — sex category). Age ≥ 75 is upgraded to 2 points (from 1 in CHADS₂), reflecting its stronger association with stroke risk.
The key advantage of CHA₂DS₂-VASc is its performance in the “intermediate” CHADS₂ = 1 group. When these patients are re-evaluated with CHA₂DS₂-VASc, many score ≥ 2 and clearly benefit from anticoagulation, while those with CHA₂DS₂-VASc 0 (males) or 1 (females) have a genuinely low stroke rate (< 1%/year) and can safely forgo anticoagulation. This better discrimination has made CHA₂DS₂-VASc the recommended tool in ESC, AHA/ACC, and NICE guidelines.
Despite this, CHADS₂ remains useful as a simpler initial screen and is still referenced in many clinical environments, particularly in primary care and emergency settings where a quick risk estimate is needed.
Step 1: Confirm non-valvular AF (exclude mechanical valves and moderate-to-severe mitral stenosis). Step 2: Calculate CHADS₂ (or preferably CHA₂DS₂-VASc). Step 3: If anticoagulation is indicated, assess bleeding risk with HAS-BLED and address modifiable factors. Step 4: Choose a DOAC (first-line) or warfarin. Step 5: Reassess risk factors periodically — CHADS₂ is not static; patients acquire new risk factors over time.
Special Populations & Considerations
Clinical takeaway: A high bleeding risk score should prompt you to address modifiable factors, not to withhold anticoagulation. The only absolute contraindication to anticoagulation is active, life-threatening bleeding. For almost all patients with AF and a CHADS₂ ≥ 2, the benefit of stroke prevention outweighs the risk of bleeding.
Common Pitfalls & Limitations
A CHADS₂ score of 0 does not guarantee a low stroke risk. In the original validation, the annual stroke rate at CHADS₂ = 0 was still 1.9% — not negligible. More importantly, CHADS₂ does not capture several established risk factors: age 65–74 (only age ≥ 75 scores a point), vascular disease (MI, PAD), and female sex. A 70-year-old woman with peripheral arterial disease and paroxysmal AF scores CHADS₂ = 0 but CHA₂DS₂-VASc = 3, clearly warranting anticoagulation. This is the fundamental limitation that led to the development and adoption of CHA₂DS₂-VASc.
The CHADS₂ score was derived and validated exclusively in non-valvular AF. Patients with mechanical prosthetic heart valves or moderate-to-severe rheumatic mitral stenosis are at very high thromboembolic risk regardless of their CHADS₂ score and require anticoagulation with warfarin (DOACs are contraindicated with mechanical valves — the RE-ALIGN trial was stopped early due to excess thromboembolic events with dabigatran vs. warfarin). The score should not be applied to these patients, and anticoagulation should not be withheld based on a low CHADS₂ in valvular AF.
It is a common clinical error to withhold anticoagulation from patients with a high HAS-BLED score or a history of GI bleeding. Many of the risk factors for stroke (age, hypertension) are also risk factors for bleeding, so the highest-risk patients for stroke are often also the highest-risk for bleeding. However, multiple studies demonstrate that net clinical benefit — stroke prevention minus excess bleeding events, weighted by severity — almost universally favours anticoagulation when CHADS₂ ≥ 2. Cardioembolic strokes are typically large, disabling, and frequently fatal, while anticoagulant-related bleeding (with the exception of ICH) is generally manageable and rarely fatal. The correct response to a high bleeding risk is to mitigate modifiable factors (control BP, stop NSAIDs, switch to a DOAC with lower GI bleeding rates like apixaban), not to leave the patient unprotected against stroke.
The CHADS₂ score is a snapshot of the patient’s risk factors at one point in time. Patients with paroxysmal AF who initially score 0 may develop hypertension, diabetes, or heart failure over time. Every clinical encounter is an opportunity to reassess. A patient who started at CHADS₂ = 0 five years ago may now be 76 with new-onset hypertension — CHADS₂ = 2 — and the anticoagulation conversation needs to be revisited. Similarly, a patient who had a TIA immediately jumps to ≥ 2 regardless of other factors.
There is a common misconception that paroxysmal AF carries a lower stroke risk than persistent or permanent AF. The evidence does not support this — stroke risk is determined by the presence of risk factors (as captured by CHADS₂ or CHA₂DS₂-VASc), not by the pattern of AF. Paroxysmal, persistent, and permanent AF carry the same annual stroke risk at any given CHADS₂ score. Anticoagulation decisions should be based on the score, regardless of AF pattern. Even brief episodes of device-detected subclinical AF (atrial high-rate episodes) may warrant anticoagulation if risk factors are present.
Quick Reference Summary
| CHADS₂ Score | Risk | Annual Stroke Rate | Recommended Action |
|---|---|---|---|
| 0 | Low | 1.9% | Re-evaluate with CHA₂DS₂-VASc. If CHA₂DS₂-VASc 0 (♂) or 1 (♀) → no anticoagulation. |
| 1 | Low-Mod | 2.8% | Re-evaluate with CHA₂DS₂-VASc. Consider anticoagulation if CHA₂DS₂-VASc ≥ 2 (♂) or ≥ 3 (♀). |
| ≥ 2 | Moderate–High | 4.0–18.2% | Oral anticoagulation recommended. DOAC preferred over warfarin for non-valvular AF. |
The Golden Rule: Every patient with AF deserves a stroke risk assessment. CHADS₂ ≥ 2 means anticoagulate. CHADS₂ 0–1 means re-evaluate with CHA₂DS₂-VASc for a more precise answer. When in doubt, the consequences of an untreated cardioembolic stroke almost always outweigh the risks of anticoagulation.
Disclaimer & References
For Educational Purposes Only. This calculator and the accompanying clinical information are intended as educational tools for healthcare professionals. They do not replace clinical judgement. Results should be interpreted in the full clinical context. Lab reference ranges vary by institution — verify with your own laboratory. Drug dosages should be confirmed against current prescribing information.
References
- Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001;285(22):2864–2870. DOI: 10.1001/jama.285.22.2864
- Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest. 2010;137(2):263–272. DOI: 10.1378/chest.09-1584
- Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. 2021;42(5):373–498. DOI: 10.1093/eurheartj/ehaa612
- January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation. 2019;140(2):e125–e151. DOI: 10.1161/CIR.0000000000000665
- Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation (RE-LY). The New England Journal of Medicine. 2009;361(12):1139–1151. DOI: 10.1056/NEJMoa0905561
- Granger CB, Alexander JH, McMurray JJV, et al. Apixaban versus warfarin in patients with atrial fibrillation (ARISTOTLE). The New England Journal of Medicine. 2011;365(11):981–992. DOI: 10.1056/NEJMoa1107039
- Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation (ROCKET AF). The New England Journal of Medicine. 2011;365(10):883–891. DOI: 10.1056/NEJMoa1009638
- Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJGM, Lip GYH. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation. Chest. 2010;138(5):1093–1100. DOI: 10.1378/chest.10-0134
- Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Annals of Internal Medicine. 2007;146(12):857–867. DOI: 10.7326/0003-4819-146-12-200706190-00007